FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 394 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR What to Know About Returning to Work After Cancer Treatment: An... February 15, 2024 Workout Wednesdays – Chest Exercises Part 1 June 10, 2020 Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab February 4, 2021 Noninferiority of OS with 3 Months Compared to 6 Months of... January 20, 2026 Load more HOT NEWS Young Women with Breast Cancer Often Forgo Hormone Therapy Due to... Hopes for the future of cancer research – a video from... “Mi corazón siempre dolerá”: Cómo honro a mi mejor amiga de... Being Diagnosed With a Childhood Cancer As an Adult Led Me...
